eligibility_summary
Inclusion: Japanese adults (≥18, biologic parents Japanese), DLBCL NOS/transformed or high‑grade with MYC and BCL2/BCL6 rearrangements, relapsed/refractory after ≥2 lines, measurable disease (Lugano), ECOG 0–2. Exclusion: Burkitt, bulky ≥10 cm, PTLD, active CNS, other active/recent cancers (some in situ/NMSC/non‑met prostate allowed), significant effusions, recent HSCT (AHSCT <30d, allo: any prior [Ph I] or <60d [Ph II]), HIV+, active HBV/HCV, recent therapy within washouts, CAR‑T <100d.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Trial tests MT-2111 (loncastuximab tesirine), an intravenous CD19-directed antibody–drug conjugate (ADC). Mechanism: a humanized anti-CD19 monoclonal IgG binds CD19 on malignant B cells, is internalized, and releases a pyrrolobenzodiazepine (PBD) dimer payload (tesirine) via a cleavable linker. The PBD creates DNA minor-groove crosslinks, blocking replication and inducing apoptosis, with potential bystander killing. Targets: CD19-expressing B cells in relapsed/refractory DLBCL. Pathways affected: antigen-specific B-cell targeting (CD19) and downstream DNA damage/repair and cell-cycle pathways leading to cell death.